Akoya Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-63.32	-70.64	-44.37	-21.76	-14.75
Depreciation & Amortization	8.89	7.15	4.79	3.82	3.06
Share-Based Compensation	10.44	7.43	4.04	0.48	0.15
Other Operating Activities	-6.9	2.57	-1.96	5.57	-2.23
Operating Cash Flow	-50.9	-53.5	-36.07	-6.84	-13.78
Capital Expenditures	-3.65	-7.31	-5.09	-3.3	-2.87
Change in Investments	7	-6.77	0	10.02	-10.02
Investing Cash Flow	3.35	-14.08	-5.09	6.73	-12.89
Share Issuance / Repurchase	48.31	0.45	138.95	0.12	0
Debt Issued / Paid	10.54	30.39	-0.32	7.99	4.43
Other Financing Activities	-2.01	-2.11	-1.59	-2.63	24.13
Financing Cash Flow	56.84	28.73	137.04	5.49	28.56
Net Cash Flow	9.29	-38.85	95.87	5.37	1.89
Free Cash Flow	-54.55	-60.8	-41.16	-10.14	-16.65
Free Cash Flow Margin	-56.45%	-81.22%	-74.95%	-23.89%	-39.41%
Free Cash Flow Per Share	-1.23	-1.61	-1.53	-4.28	-7.31

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).